Drug Patents owned by Exelixis

1. Drug name - COMETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7579473 EXELIXIS c-Met modulators and methods of use
Aug, 2026

(3 years from now)

US11091439 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(7 years from now)

US8877776 EXELIXIS (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(8 years from now)

CN102388024A EXELIXIS Malate Salt Of N-(4-{[6,7-Bis (Methyloxy) Quinolin-4-Yl] Oxy} Phenyl-N'-(4-Fluorophenyl) Cyclopropane-1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Or Cancer
Sep, 2019

(3 years ago)

CN106083714B EXELIXIS N --(4 - [6, 7 --(Methyl Oxy) Quinoline - -4--- Yl] Oxy} Phenyl) -N '--(4 - - Fluorophenyl) -1, 1-Dimethanamide Malate And Its Crystalline
May, 2022

(5 months ago)

CN106083714A EXELIXIS N - (4 - {[6, 7-Bis - (Methyl) -4 - Yl] Oxy} Phenyl) -N '-(4) -1, 1 -- Dicarboxamide Malate And Its Crystal
May, 2022

(5 months ago)

EP2392565A1 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2210607A1 EXELIXIS N-[3-Fluoro-4-({6-(Methyloxy)-7-[(3-Morpholin-4-Ylpropyl)Oxy]Quinolin-4-Yl}Oxy)Phenyl]-N'-(4-Fluorophenyl)Cyclopropane-1,1-Dicarboxamide For The Treatment Of Cancer
Sep, 2024

(1 year, 11 months from now)

EP2210607B1 EXELIXIS N-[3-Fluoro-4-({6-(Methyloxy)-7-[(3-Morpholin-4-Ylpropyl)Oxy]Quinolin-4-Yl}Oxy)Phenyl]-N'-(4-Fluorophenyl)Cyclopropane-1,1-Dicarboxamide For The Treatment Of Cancer
Sep, 2024

(1 year, 11 months from now)

EP1673085A4 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP3329918A3 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2409704B1 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2392565B1 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2392564A1 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP3329918A2 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP1673085B1 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2409704A3 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2392564B1 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP1673085A2 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2409704A2 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP3329918B1 EXELIXIS C-Met Modulators And Methods Of Use
Sep, 2024

(1 year, 11 months from now)

EP2213661B1 EXELIXIS C-Met Modulators And Methods Of Use
Mar, 2029

(6 years from now)

EP2213661A1 EXELIXIS C-Met Modulators And Methods Of Use
Mar, 2029

(6 years from now)

EP2387563A1 EXELIXIS Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563B2 EXELIXIS Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

EP2387563B1 EXELIXIS Malate Salt Of N- (4- { [ 6, 7-Bis (Methyloxy) Quinolin-4-Yl]Oxy}Phenyl-N' - (4 -Fluorophenyl) Cyclopropane-1,1-Dicarboxamide, And Crystalline Forms Thereof For The Treatment Of Cancer
Jan, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

US11091440 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer Jan, 2030

(7 years from now)

US9717720 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Feb, 2032

(9 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Treatment: Method of treating medullary thyroid cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.